tetano
Editor, Senior Moderator
Peptides. 2020 May 4:170328. doi: 10.1016/j.peptides.2020.170328. [Epub ahead of print]
In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2.
Ling R[SUP]1[/SUP], Dai Y[SUP]1[/SUP], Huang B[SUP]1[/SUP], Huang W[SUP]1[/SUP], Lu X[SUP]2[/SUP], Jiang Y[SUP]3[/SUP].
Author information
Abstract
An outbreak caused by 2019 novel coronavirus (2019-nCoV) was first identified in Wuhan City, Hubei Province, China. The new virus was later named SARS-CoV-2. The virus has affected tens of thousands of patients in the world. The infection of SARS-CoV-2 causes severe pneumonia and even death. It is urgently needed to find a therapeutic method to treat patients with SARS-CoV-2 infection. Studies showed that the surface spike (S) protein is essential for the coronavirus binding and entry of host cells. The heptad repeats 1 and 2 (HR1 and HR2) in the S protein play a decisive role in the fusion of the viral membrane with the host cell membrane. We predicted the HR1 and HR2 regions in S protein by sequence alignment. We simulated a computational model of HR1/2 regions and the fusion core. The binding energy of HR1 and HR2 of the fusion core was -33.4kCal/mol. We then designed antivirus peptides by molecular dynamics simulation of the fusion core. The binding energy of HR2-based antiviral peptide to HR1 was -43.0kCal/mol, which was stronger than the natural stage of the fusion core, suggesting that the predicted antiviral peptide can competitively bind with HR1 to prevent forming of the fusion core. The antiviral peptides can prevent SARS-CoV-2 membrane fusion and can potentially be used for the prevention and treatment of infections.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Blocking peptide; Molecular Dynamics; SARS-CoV-2; Spike protein
PMID:32380200DOI:10.1016/j.peptides.2020.170328
In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2.
Ling R[SUP]1[/SUP], Dai Y[SUP]1[/SUP], Huang B[SUP]1[/SUP], Huang W[SUP]1[/SUP], Lu X[SUP]2[/SUP], Jiang Y[SUP]3[/SUP].
Author information
Abstract
An outbreak caused by 2019 novel coronavirus (2019-nCoV) was first identified in Wuhan City, Hubei Province, China. The new virus was later named SARS-CoV-2. The virus has affected tens of thousands of patients in the world. The infection of SARS-CoV-2 causes severe pneumonia and even death. It is urgently needed to find a therapeutic method to treat patients with SARS-CoV-2 infection. Studies showed that the surface spike (S) protein is essential for the coronavirus binding and entry of host cells. The heptad repeats 1 and 2 (HR1 and HR2) in the S protein play a decisive role in the fusion of the viral membrane with the host cell membrane. We predicted the HR1 and HR2 regions in S protein by sequence alignment. We simulated a computational model of HR1/2 regions and the fusion core. The binding energy of HR1 and HR2 of the fusion core was -33.4kCal/mol. We then designed antivirus peptides by molecular dynamics simulation of the fusion core. The binding energy of HR2-based antiviral peptide to HR1 was -43.0kCal/mol, which was stronger than the natural stage of the fusion core, suggesting that the predicted antiviral peptide can competitively bind with HR1 to prevent forming of the fusion core. The antiviral peptides can prevent SARS-CoV-2 membrane fusion and can potentially be used for the prevention and treatment of infections.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Blocking peptide; Molecular Dynamics; SARS-CoV-2; Spike protein
PMID:32380200DOI:10.1016/j.peptides.2020.170328